Yevgeniy R. Semenov

Mar 13, 2024 | jamanetwork.com | Adewole S. Adamson |Yevgeniy R. Semenov |Hannah Rashdan

Adjuvant Immunotherapy in Stage II Melanoma—Further Risk Stratification is Needed Currently, most patients with stage IIB and IIC melanoma are treated with surgery and undergo subsequent routine surveillance for disease recurrence by dermatologists. However, the recent US Food and Drug Administration approval of immune checkpoint inhibitors (ICIs) as adjuvant therapy in this population is causing a paradigm shift in the management of patients with localized melanoma.

Feb 9, 2023 | healio.com | Gabrielle Capaldo |Kristen Dowd |Yevgeniy R. Semenov

Source/Disclosures We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Cutaneous immune-related adverse events are associated with increased survival rates among immune checkpoint inhibitor recipients, particularly in patients with melanoma, according to a study. “Immune checkpoint blockade has become the standard of care for a growing number of advanced cancers,” Yevgeniy R.